The Ordinary Argireline Solution 10% | Anti-Aging Serum | Botox Alternate | for Fine Lines and Wrinkles
Discover the powerful anti-aging benefits of The Ordinary Argireline Solution 10%. Reduce fine lines, wrinkles, and signs of aging with this advanced peptide formula. Perfect for smoother, younger-looking skin.This lightweight, water-based solution offers a non-invasive alternative to Botox, delivering visible results in areas prone to facial expressions.
Main Features & Benefits:
- Peptide-Powered Formula: The Ordinary Argireline Solution 10% is packed with a high concentration of Argireline, a powerful peptide known to relax facial muscles and reduce the appearance of wrinkles caused by repeated facial expressions.
- Botox-like Results: Achieve a smoother complexion without the need for injections. This solution is often referred to as “Botox in a bottle” due to its ability to minimize dynamic wrinkles.
- Targeted Application: Designed to be applied around the eyes, forehead, and areas prone to movement, The Ordinary Argireline Solution 10% works where itโs needed most to soften fine lines.
- Lightweight & Fast-Absorbing: This water-based serum absorbs quickly, making it perfect for layering with other skincare products. It feels lightweight on the skin, leaving no residue.
- Suitable for All Skin Types: Whether you have oily, dry, combination, or sensitive skin, this formula is gentle and effective for all.
- Cruelty-Free & Vegan: Like all products from The Ordinary, this solution is cruelty-free, vegan, and free from harmful additives such as parabens, sulfates, and alcohol.
How to Use:
- Apply a few drops of The Ordinary Argireline Solution 10% to the forehead and around the eyes in the morning and evening before moisturizing.
- Consistent use will lead to visibly smoother skin with fewer fine lines and wrinkles.
Key ingredients:
ย ย ย ย 1. Acetyl Hexapeptide-8
ย ย ย ย 2. Collagen
The Ordinary Argireline Solution 10% now available at Agetune & home delivered all over Bangladesh.
Reviews
There are no reviews yet.